New eczema shot for kids enters testing phase
NCT ID NCT05388760
Summary
This trial is studying a drug called tralokinumab, given as an injection, to see how it behaves in the body and if it is safe and effective for children aged 6 to 12 with moderate-to-severe eczema. It will involve about 24 children and last for up to 194 weeks, including treatment and follow-up visits. The main goals are to measure drug levels in the blood and track any side effects, while also checking if it helps improve eczema symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
LEO Pharma Investigational Site
Brno, 625 00, Czechia
-
LEO Pharma Investigational Site
Prague, 150 06, Czechia
-
LEO Pharma Investigational Site
Reims, Ardennes, 51100, France
-
LEO Pharma Investigational Site
Rotterdam, 3011 TG, Netherlands
-
LEO Pharma Investigational Site
Utrecht, 3584 CX, Netherlands
-
LEO Pharma Investigational Site
Cadiz, Andalusia, 11009, Spain
-
LEO Pharma Investigational Site
Esplugues de Llobregat, Barcelona, 08950, Spain
-
LEO Pharma Investigational Site
Alicante, 03010, Spain
-
LEO Pharma Investigational Site
Manchester, Greater Manchester, M13 9WL, United Kingdom
-
LEO Pharma Investigational Site
London, SE1 9RT, United Kingdom
-
LEO Pharma Investigational Site
Sheffield, S10 2TH, United Kingdom
Conditions
Explore the condition pages connected to this study.